• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

PSME1 Recombinant Monoclonal Antibody

The recombinant antibody against PSME1 was produced using a synthesized peptide derived from human PSME1 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, IHC, IF, FC.

ADC-56685A

The recombinant antibody against PSME1 was produced using a synthesized peptide derived from human PSME1 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, IHC, IF, FC.

$350.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-56685A ClonalityMonoclonal
Target NamePSME1Target SynonymsIFI5111, PSME1
FormLiquidSpecies ReactivityHuman
IsotypeRabbit IgGStorage BufferPH 7.4, 0.02% sodium azide and 50% glycerol., 150mM NaCl, Rabbit IgG in phosphate buffered saline
Purification MethodAffinity-chromatography purifiedConjugateNon-conjugated
ApplicationELISA, IF, IHC, WB, FCStorageUpon receipt

Immunogen Information


Immunogen DescriptionA synthesized peptide derived from human PSME1Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ06323
Background Information
  • Uniprot Id

    Q06323

  • Target Species

    Human

  • Target Name

    PSME1

  • Target Full Name

    Proteasome activator complex subunit 1

  • Target Function

    Implicated in immunoproteasome assembly and required for efficient antigen processing. The PA28 activator complex enhances the generation of class I binding peptides by altering the cleavage pattern of the proteasome.

  • Target Protein Families

    PA28 family

  • Target Research Area

    Cell Biology

  • Target Synonyms

    11S regulator complex alpha subunit; 11S regulator complex subunit alpha; 29 kD MCP activator subunit; 29kD MCP activator subunit; Activator of multicatalytic protease subunit 1; IFI5111; IGUP I-5111; Interferon gamma IEF SSP 5111; Interferon gamma inducible protein 5111; Interferon gamma up regulated I 5111 protein; Interferon gamma up-regulated I-5111 protein; MGC8628; PA28a; PA28alpha; Proteasome (prosome, macropain) activator subunit 1 (PA28 alpha); Proteasome activator 28 subunit alpha; Proteasome activator complex subunit 1; Proteasome activator subunit 1; PSME1; PSME1_HUMAN; REG-alpha; REGalpha

  • Target Background

    The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. The immunoproteasome contains an alternate regulator, referred to as the 11S regulator or PA28, that replaces the 19S regulator. Three subunits (alpha, beta and gamma) of the 11S regulator have been identified. This gene encodes the alpha subunit of the 11S regulator, one of the two 11S subunits that is induced by gamma-interferon. Three alpha and three beta subunits combine to form a heterohexameric ring. Alternative splicing results in multiple transcript variants.

Inquire PSME1 Recombinant Monoclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification